Aug 22, 2026·Score 91·Type A — Value-style analysisUsed for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$57.76
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$65.00($60.00–$70.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$92.50
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type A - Maximus, Inc. (MMS) 20260822 Stock Analysis
📅 Maximus Key Upcoming Events
August 31, 2026Quarterly Cash Dividend Payment (Confirmed)
Description: Maximus will distribute its regular quarterly cash dividend of $0.33 per share (translating to a $1.32 annualized payout) to shareholders of record as of August 14, 2026. This distribution underscores the company’s steadfast commitment to returning capital to shareholders, maintaining a reliable income stream even as it navigates temporary working capital constraints and pursues aggressive share repurchases.
November 19, 2026Q4 2026 Earnings Release (Estimated)
Description: This earnings event serves as a critical inflection point for Maximus. The market will intensely scrutinize the fourth-quarter release for concrete evidence that the U.S. Services segment has successfully returned to positive mid-single-digit organic growth, driven by Medicaid population activities and legislative-driven program changes. Furthermore, analysts will demand formal guidance for fiscal year 2027 and commentary regarding the ongoing resolution of the Veterans Affairs Medical Disability Exam (VA MDE) contract rebid.
December 31, 2026Expiration of VA MDE Performance Incentive Pause (Estimated)
Description: The customer-directed temporary pause on performance incentives for the highly lucrative VA MDE program is scheduled to run through the end of calendar 2026, aligning with the current contract’s conclusion. The transition to the successor contract is the single most critical milestone for Maximus’s margin recovery, as the reinstatement of these incentives is necessary to restore the $0.35 per share in earnings power that was stripped from the fiscal 2026 guidance.
🏢 Step 1: Maximus Company Overview & Business Model
Q1-A1. What is Maximus?
Company Name (Ticker): Maximus, Inc. (MMS)
Sector: Industrials
Exchange: NYSE
Founded: 1975
Listing Date: June 13, 1997
Fiscal Year End: September
Headquarters: United States, McLean
CEO: Bruce Caswell
Market Cap: $3.02B
Shares Outstanding: 52.36M
Current Stock Price:$57.76
Annual Dividend Yield:2.43%
Ex-dividend Date: August 14, 2026 (ET, historical basis)
As-of: August 22, 2026 (ET)
Q1-A2. How Does Maximus Make Money?
Core Business Model: Maximus generates the vast majority of its revenue by serving as an indispensable administrative and technological partner to government agencies globally. The company operates as a premier business process outsourcing (BPO) and consulting firm, translating complex health and human services public policies into scalable, highly efficient operating models.
Key Offerings: Revenue is secured through long-term, multi-year contracts to manage large-scale health insurance eligibility and enrollment programs (such as Medicaid, Medicare, and CHIP), independent clinical assessments, medical appeals, and broad-based program integrity services. The firm effectively acts as the operational bridge between federal/state legislatures and the citizens receiving entitlement benefits.
Value Proposition to Clients: Maximus enables federal, state, and local governments to dramatically enhance citizen service delivery, ensure strict regulatory compliance, and permanently reduce administrative overhead. By leveraging proprietary technology, integrating sophisticated artificial intelligence (AI) triage tools, and deploying specialized human labor, Maximus achieves operational scale and accuracy metrics that underfunded public agencies simply cannot replicate internally.
Q1-A3. Maximus’s Revenue Segments & Core Income Sources
U.S. Federal Services (≈58.0% of Revenue): This segment is the undisputed core growth engine of the company, generating $3.07 billion in fiscal year 2025 and $721 million in Q3 2026. It derives income by delivering clinical services, complex appeals management, and comprehensive technology solutions to federal agencies. A massive driver of this segment’s historical profitability has been the VA MDE program. Looking forward, the segment is pivoting aggressively to capture a $47 billion addressable market in defense and national security, securing notable recent wins at the Air Force and TSA.
U.S. Services (≈32.5% of Revenue): Producing $1.76 billion in fiscal year 2025 and $418 million in Q3 2026, this division focuses exclusively on state and local governments. It administers public assistance programs, Medicaid enrollment, and child support enforcement services. Recent top-line performance suffered a structural contraction following the completion of the pandemic-era continuous enrollment unwinding (which provided a temporary volume surge). However, the segment is now shifting toward normalized outreach and engagement work, driven by stringent new legislative mandates for Medicaid and SNAP beneficiaries.
Outside the U.S. (≈9.5% of Revenue): Contributing roughly $600 million in FY25 and $140 million in Q3 2026, this segment provides employment and clinical services to international governments, predominantly in the United Kingdom, Australia, and Canada. Following strategic divestitures of underperforming, margin-dilutive employment service businesses in Australia and South Korea, this unit has purposefully shrunk its top-line contribution to focus strictly on clinical margin expansion and break-even operational stability.
Q1-A4. Who Are Maximus’s Competitors?
Direct Competitors in Government Services: Maximus fiercely competes with pure-play government contractors and federal consulting firms. Key rivals include Booz Allen Hamilton (BAH), CACI International (CACI), ICF International (ICFI), and Leidos (LDOS). While these peers lean heavily into general IT modernization, systems engineering, and defense/intelligence contracting, Maximus holds a highly differentiated, specialized, and defensible niche in health and human services administration.
BPO and Technology Substitutes: The company also faces intense competition from broad-based IT services and business process outsourcing giants such as Accenture (ACN), Cognizant (CTSH), and Conduent (CNDT). These firms frequently bid on large-scale state and federal administrative system overhauls and data processing contracts, threatening Maximus’s market share on broader digital transformation initiatives.
Industry Position: Maximus possesses a dominant, near-monopoly moat in specific specialized verticals, such as state-level Medicaid enrollment, where it commands massive market share due to its decades-long track record and intricate, state-specific regulatory expertise. Its competitive positioning has recently been fortified by the aggressive integration of AI and automation into its contact center (Total Experience Management, or TXM) and assessment workflows, achieving superior cost efficiencies that allow it to underbid generalized IT firms while protecting internal margins.
Q1-A5. Maximus Key Events: Past 12 Months
August 06, 2026Q3 2026 Earnings Release
Description: Maximus reported revenue of $1.28 billion (a 5.1% YoY decline) and adjusted EPS of $2.22. While the company beat bottom-line profit estimates, it fell short on sales. Most critically, management was forced to drastically slash full-year EPS guidance by approximately $0.35 per share (from an $8.40 midpoint down to $8.05) due to a sudden suspension of VA MDE performance incentives, triggering a violent 9% drop in the stock price.
July 01, 2026Temporary Modification and Pause of VA MDE Incentives
Description: The Department of Veterans Affairs unilaterally notified vendors of a temporary pause in performance incentives and disincentives on the Medical Disability Exam program, active through December 31, 2026. As the agency overhauls its invoice review and validation processes, this administrative action immediately removed a highly profitable, high-margin revenue stream from Maximus’s near-term forecast.
May 07, 2026Q2 2026 Earnings Release
Description: Maximus delivered a strong quarter featuring robust margin expansion driven explicitly by in-house AI efficiencies and automation rollouts. The strong fundamental performance led management to raise FY26 earnings guidance at the time and announce a massive, highly accretive new $400 million share repurchase authorization.
April 24, 2026Appointment of Elizabeth Moellering as General Counsel
Description: The company solidified its executive leadership team by promoting Moellering to General Counsel and Corporate Secretary. Following her successful tenure as Interim General Counsel and Head of Litigation—where she built a disciplined structure for managing legal disputes and navigated complex federal regulatory frameworks—her permanent appointment signaled a stabilization of the executive suite.
February 06, 2026Q1 2026 Earnings Release
Description: The firm reported a 5.7% YoY revenue increase to $1.40 billion, driven fundamentally by elevated clinical assessment volumes within the U.S. Federal Services segment. Demonstrating relentless confidence in intrinsic value, the company aggressively purchased 3.1 million shares of its own stock for $237 million during the quarter, heavily depleting the prior buyback authorization.
November 20, 2025Q4 and Full Year 2025 Earnings Release
Description: Maximus concluded fiscal year 2025 with $5.43 billion in total revenue and an impressive 12.9% adjusted EBITDA margin. This record-setting year was propelled primarily by a 12.1% surge in U.S. Federal Services revenue, validating the company’s strategic pivot toward clinical programs and high-value federal mandates.
Q1-A6. Step 1 Key Takeaways
Step 1 Summary: Maximus operates a highly defensive, immensely cash-generative business model dominating the specialized niche of government health and human services administration. However, the recent unilateral, customer-directed administrative pause on lucrative VA contract incentives has violently reset near-term earnings expectations, temporarily overshadowing the profound underlying margin improvements driven by the company’s rapid deployment of AI and automation workflows.
Top 3 Red Flags:
1 The unilateral pause on VA MDE performance incentives exposes extreme revenue concentration risk, highlighting the fragility of high-margin federal contract components to sudden bureaucratic shifts.
2 Prolonged administrative delays at a major federal customer caused Days Sales Outstanding (DSO) to spike severely to 98 days in Q3 2026, resulting in a damaging, albeit temporary, $137 million free cash flow outflow.
3 The structural decline in the U.S. Services segment’s top line—following the expiration of pandemic-era Medicaid redetermination volumes—creates a tough growth hurdle that requires rapid replacement by new state-level legislative mandates.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 Adjusted EBITDA Margin trajectory (currently projected at ≈13.7% for the full FY26, testing the durability of AI efficiency gains against the incentive pause).
2 Cash collection velocity and DSO normalization (management’s firm target is to crush DSO back below 70 days by fiscal year-end).
3 Total pipeline size and win rates (monitoring the translation of the massive $50.4 billion total pipeline and $1.35 billion in awarded-but-unsigned contracts into realized revenue).
4 Buyback execution pace (tracking the depletion of the $400 million active share repurchase authorization against the currently depressed share price).
5 Organic revenue growth rate of the U.S. Services segment (verifying management’s forecast of a return to positive growth in Q4 2026).
Top 3 Unconfirmed and Estimated:
1 The exact pricing, performance structure, and vendor geographic allocation of the upcoming VA MDE successor contract (rebid expected to resolve in early FY27, which will dictate the permanent margin baseline).
2 The precise timeline, magnitude, and conversion rate of revenue contributions from newly awarded defense and national security contracts outside the company’s traditional health services niche.
3 The speed and willingness with which state governments will implement complex federal Medicaid and SNAP work requirements under H.R. 1 legislation, which directly drives the U.S. Services segment’s growth.
🏰 Step 2: Maximus’s Economic Moat, Growth & Capital Allocation
Q2-A1. Does Maximus Have a Durable Economic Moat?
Entry barriers: Maximus possesses a profound, wide economic moat built upon insurmountable intangible assets, immense switching costs, and regulatory capture. The administration of life-sustaining programs like Medicaid, clinical disability appeals, and federal welfare requires deep, highly specialized regulatory expertise intertwined with massive, secure IT infrastructures. Competitors attempting to enter this space face a multi-year learning curve and grueling, expensive compliance certifications (such as the Cybersecurity Maturity Model Certification, or CMMC Level 2) just to be eligible to bid against Maximus. Furthermore, replacing an incumbent provider that currently handles sensitive, mission-critical citizen health data creates massive operational and political risk for inherently risk-averse government agencies, thereby cementing customer retention and establishing a nearly unbreakable vendor lock-in cycle.
Pricing power: While traditional commercial pricing power is structurally constrained by the rigid, highly scrutinized nature of fixed-price or cost-plus government procurement contracts, Maximus exercises a potent form of pseudo-pricing power through extreme operational leverage. The company successfully designs and implements proprietary AI-enabled tools and workflow automation across its contact centers and processing hubs. By executing these efficiencies, Maximus has improved operating margins by up to 3.5% on existing contracts without needing to negotiate higher top-line prices with the government, effectively expanding profits from the inside out.
Profitability defense: The ultimate proof of a moat lies in capital efficiency. The company consistently maintains a Return on Invested Capital (ROIC) of roughly 12.0% to 13.5%, drastically outpacing its estimated 6.1% to 7.4% weighted average cost of capital (WACC). This sustained, multi-year spread is conclusive evidence of a durable moat, proving that Maximus successfully extracts excess economic returns despite operating within the highly competitive, lowest-bidder dynamics of the federal procurement environment.
Q2-A2. Is Maximus’s Growth Sustainable?
Industry Structure and Growth Outlook: Maximus operates in a mature but structurally expanding industry supported by an astonishingly large Total Addressable Market (TAM). The company’s immediate pipeline of sales opportunities stands at a staggering $50.4 billion, with completely new work comprising a healthy 57% of that total. Recognizing the limitations of its traditional health and human services sandbox, the company is actively and successfully penetrating a massive $47 billion adjacent TAM in the defense and national security sectors. Structural, long-term growth drivers include the irreversible, bipartisan mandate for the digitization of citizen services, as well as relentless demographic shifts (such as an aging population and rising chronic illness rates) that mechanically increase the volume of healthcare entitlement claimants requiring processing.
Growth Sustainability: Long-term top-line growth is highly sustainable, typically compounding at a mid-single-digit cadence. However, the nature of this growth is inherently “lumpy” and event-driven. The revenue trajectory is frequently disrupted by the binary nature of mega-contract awards, competitor protests that freeze implementations, and perennial federal budget continuing resolutions that delay new spending. Consequently, investors must endure significant quarter-to-quarter volatility in exchange for long-term compounding.
Downside scenarios:
1 A sweeping, ideologically driven federal or state mandate to reverse privatization and insource administrative services, aggressively reducing the pool of outsourced clinical assessments available to commercial vendors.
2 Severe, prolonged federal budget gridlock that completely freezes new procurement cycles, forcing agencies into endless, low-margin, short-term bridge contracts that destroy Maximus’s ability to forecast revenue and scale operations.
3 The catastrophic failure to retain the massive VA MDE contract during the upcoming recompete phase. Losing primary regions to competitors would materially and permanently impair the U.S. Federal Services segment’s baseline revenue and margin profile.
Q2-A3. How Does Maximus Allocate Capital & Return Cash?
Priorities and consistency: Management’s capital allocation framework is exceptionally disciplined, mathematically sound, and heavily favors aggressive share repurchases combined with steady dividend payments over reckless, transformative M&A. The company acts with extreme counter-cyclical precision, directing excess free cash flow immediately toward shrinking the float whenever the stock screens as undervalued.
Shareholder Returns: Maximus exhibits elite shareholder yield characteristics that rank in the upper echelon of the industrials sector. In fiscal 2025, the company aggressively repurchased 5.8 million shares for $457 million, permanently retiring over 10% of its equity base in a single year. In Q3 2026, despite cash flow headwinds, it retired an additional 0.75 million shares for $50 million and retains a massive $400 million active authorization, representing roughly 13% of the current depressed market capitalization. Furthermore, the company pays a rock-solid $1.32 annual dividend, yielding an attractive 2.43%. Total shareholder yield comfortably exceeds 9%, vastly outperforming risk-free treasury benchmarks and providing a massive safety net for long-term holders.
Reinvestment Efficacy: While returning massive quantities of cash to owners, Maximus continues to deploy capital highly efficiently into organic AI infrastructure and strategic, bolt-on acquisitions. A prime example is the highly successful $1.4 billion acquisition of Veterans Evaluation Services, which deeply entrenched Maximus into the VA ecosystem and continues to generate ROIC figures well above the industry median, proving that management only acquires when the strategic fit and financial accretion are irrefutable.
Q2-A4. Step 2 Key Takeaways
Scoring Rationale:
Economic Moat (9/10): Entrenched government relationships, massive operational switching costs, and deep regulatory expertise create near-monopoly positioning in specific health services, though the rigidity of government procurement caps absolute, unconstrained pricing power.
Growth Sustainability (6/8): The $50.4B pipeline is undeniably robust, and the new defense expansion offers massive TAM optionality. However, chronic federal procurement delays, continuing resolutions, and lumpy mega-contract cycles inject severe, unavoidable near-term volatility into the growth narrative.
Capital Allocation (7/7): Management executes a flawless, shareholder-aligned playbook of aggressive, counter-cyclical share repurchases combined with a highly secure, growing dividend, mathematically maximizing long-term per-share value.
Step 2 Summary: Maximus possesses a dominant, highly defensible business model fortified by a wide, specialized moat. While top-line growth is subject to the unpredictable friction and delays inherent in government contracting, management compensates flawlessly by aggressively returning immense free cash flow to shareholders through massive, opportunistic buybacks at discounted valuations.
💰 Step 3: Is Maximus Profitable? Financial Health Analysis
Q3-A1. Maximus’s Growth & Profitability Trends
Revenue and Earnings trajectory: Between fiscal year 2022 and fiscal year 2025, total revenue expanded steadily from $4.63 billion to $5.43 billion (representing a 3-year compound annual growth rate of approximately 5.5%). However, trailing twelve-month (TTM) revenue as of Q3 2026 contracted slightly to $5.25 billion. This contraction was not a loss of market share, but rather driven entirely by the predictable roll-off of pandemic-era disaster support contracts and the completion of the massive Medicaid unwinding surge, which artificially inflated prior-year comparisons. In stark contrast to the recent top-line softening, earnings per share (EPS) surged massively from $3.29 in FY22 to $6.74 TTM, highlighting a dramatic structural improvement in underlying business profitability.
Profitability margin and leverage: Maximus exhibits excellent, expanding operating leverage. From FY23 through FY25, gross margins widened significantly from 21.0% to 24.6%, while core operating margins expanded from 6.0% to 9.7%. Even amidst the Q3 2026 revenue decline, the consolidated adjusted EBITDA margin actually rose year-over-year to 15.0%, and the U.S. Federal Services operating margin hit an impressive 18.6%. This data conclusively proves that the aggressive integration of AI-enabled tools and automation is fundamentally decoupling profit growth from raw headcount expansion, allowing Maximus to extract more margin from flat or declining revenue streams.
Q3-A2. How Profitable Is Maximus? (Margins & ROIC)
ROIC and Value Creation: Maximus is a highly profitable compounder of capital. The TTM Return on Invested Capital (ROIC) stands at an impressive 13.27% (or 12.15% based on annualized Q3 2026 specific data). When juxtaposed against an estimated Weighted Average Cost of Capital (WACC) of 6.13% to 7.42%, Maximus commands a wide, deeply positive spread of over 500 basis points. This spread is the ultimate hallmark of a wide-moat compounder, clearly signifying robust, sustainable economic value creation.
Equity and Asset Efficiency: The company boasts a stellar Return on Equity (ROE) of 21.11% and a solid Return on Assets (ROA) of 8.20%. Both of these metrics substantially exceed the normative benchmarks for the broader, highly fragmented business services sector, proving that the firm holds a profound operational efficiency advantage over its less specialized, generalized IT outsourcing peers.
Q3-A3. What Drives Maximus’s Returns? (ROIC Breakdown)
Labor Efficiency and Technology Integration: As a human capital-intensive business process outsourcing provider, Maximus’s efficiency has traditionally been strictly governed by headcount utilization and wage inflation. However, the core, transformative driver of the recent ROIC expansion is the aggressive, enterprise-wide deployment of AI and workflow automation. By automating routine administrative triage, document processing, and initial citizen contact interactions, Maximus has drastically reduced its direct cost-to-serve. This technological pivot directly lifts the company’s Net Operating Profit After Tax (NOPAT) without requiring capital-heavy tangible asset investments, fundamentally altering the unit economics of its government contracts.
Working Capital Cycle: Beyond labor efficiency, Maximus’s capital efficiency is heavily dictated by Days Sales Outstanding (DSO) due to the notoriously slow, bureaucratic payment cycles of the federal government. Maintaining a tight, predictable cash conversion cycle is the critical lever for driving higher capital turnover and funding the aggressive share repurchase program.
Q3-A4. Are Maximus’s Earnings High Quality?
Cash Conversion and Profit Quality: Historically, Maximus converts its accounting profits into hard cash at an elite, highly reliable rate. In fiscal year 2025, operating cash flow (OCF) was a massive $429.4 million against reported net income of $319.0 million, yielding a superb cash conversion ratio of approximately 1.35x. This proves that the earnings are backed by real cash generation, not aggressive accounting accruals or fictitious gains.
Recent DSO Friction: In Q3 2026, profit quality faced a severe, acute stress test. Operating cash flow plummeted to a negative $125 million as DSO ballooned violently to 98 days. This was caused entirely by severe administrative and processing delays at a single major federal customer. However, this discrepancy is strictly a mechanical timing issue, not a fundamental deterioration in the client relationship or the viability of the receivables; the company explicitly collected $245 million from this specific client immediately in July, ensuring cash flow aligns tightly with book earnings over the normalized trailing twelve-month horizon.
Q3-A5. Is Maximus’s Balance Sheet Healthy? (Debt & Leverage)
Leverage Adequacy: The balance sheet is impeccably managed and heavily fortified. Gross debt stands at $1.65 billion, which translates to a Net Debt / EBITDA ratio of approximately 2.0x to 2.35x. This leverage profile sits comfortably and securely within management’s conservative, stated target range of 2.0x to 3.0x, providing immense strategic flexibility.
Liquidity and Solvency: The company holds a robust current ratio of 2.42 and a quick ratio of 2.12, showcasing immense short-term liquidity capable of easily absorbing acute working capital shocks (like the Q3 DSO spike). Furthermore, interest coverage is extremely safe at 6.49x, confirming that the company’s operating profits can easily and redundantly absorb the roughly $85 million in annual interest expenses. Systemic refinancing, credit crunch, and bankruptcy risks are functionally non-existent.
Q3-A6. Step 3 Key Takeaways
Scoring Rationale:
Profitability·Capital Efficiency (10/10): Elite structural margin expansion and a massive, sustained ROIC-WACC spread conclusively prove that AI-driven operating leverage is genuinely transforming the bottom line and permanently decoupling profit from raw revenue growth.
Cash Flow·Profit Quality (7/8): Generally outstanding, converting earnings to cash at >1.3x. However, a minor mechanical deduction is applied for the severe, albeit temporary, Q3 DSO spike that dragged quarterly OCF into negative territory, highlighting the working capital risks of federal concentration.
Financial Soundness·Debt Management (7/7): The balance sheet is an absolute fortress, with leverage anchored strictly at 2.0x, massive liquidity buffers, and interest obligations that are easily serviced by robust operating profits.
Step 3 Summary: Maximus operates an elite, highly profitable, cash-generative engine. Despite a fleeting working capital glitch in Q3 caused by federal bureaucracy, the company’s underlying structural margin expansion, superb ROIC, and fortress balance sheet indicate exceptional financial health and operational superiority over generalized peers.
🔎 Step 4: Maximus Forensic Accounting & Dilution Review
Q4-A1. Does Maximus Have Accounting Red Flags?
Revenue recognition: not found
Evidence: The company utilizes standard percentage-of-completion and transaction-based volume recognition typical for massive government contractors; comprehensive reviews of SEC filings (10-K, 10-Q) reveal absolutely no restatements, aggressive front-loading of revenue, or SEC comment letters regarding revenue irregularities.
Cost capitalization: not found
Evidence: Capital expenditures are remarkably low (consistently under $40 million annually), and software development capitalization remains immaterial and highly consistent with historical trends, proving that management is not hiding routine operating expenses on the balance sheet.
Sharp increase in accounts receivable and inventory: discovered
Evidence: Unbilled receivables and Days Sales Outstanding (DSO) spiked violently to an uncomfortable 98 days in Q3 2026, causing a massive operating cash outflow of $125 million for the quarter. However, this was explicitly traced and verified as a purely administrative invoice processing delay at a single federal agency. Validating the integrity of the receivables, $245 million was definitively cleared and collected in cash in the weeks immediately following the quarter close.
Non-recurring adjustment (normalization): not found
Evidence: The gap between GAAP and Non-GAAP EPS (e.g., $1.95 GAAP vs $2.22 Adjusted in Q3 2026) is driven purely by standard, transparent, and predictable amortization of acquired intangible assets stemming from historical, strategic M&A (like the Veterans Evaluation Services acquisition). There are no suspicious, recurring “one-time” restructuring charges hiding poor operational performance.
Q4-A2. Is Maximus Overspending? (Capex & Capital Cycle)
➖ Not applicable: Maximus is an asset-light services and technology firm, not a heavy industrial manufacturer. Its primary investments are entirely in human capital, proprietary software, and scalable AI infrastructure. With total annual CapEx sitting below $40 million, the company is entirely immune to industrial capital cycle traps, capacity gluts, massive depreciation burdens, or the oversupply dynamics that plague traditional cyclical sectors.
Q4-A3. How Sound Is Maximus’s Cash Flow?
Quality and Dependence: Over normalized multi-year periods, free cash flow (FCF) structurally exceeds 100% of reported net income. Because the business requires minimal capital expenditure to maintain and expand operations, the cash generated is entirely discretionary. The terrifying Q3 2026 negative cash flow event (-$137 million FCF) was entirely a working capital distortion caused by delayed federal payments, not a fundamental operational bleed, and was resolved fully post-quarter. Crucially, the company does not rely on external equity or debt financing to fund its core operations; rather, it uses its debt facility strictly as a tactical bridge to execute opportunistic, highly accretive share repurchases when the stock trades below intrinsic value.
Q4-A4. Is Maximus Diluting Shareholders?
⏪ Confirmed (Past) Dilution: Maximus is fiercely and aggressively anti-dilutive. Demonstrating ruthless capital discipline, the company retired roughly 5.8 million shares (representing over 10% of the entire float) in fiscal year 2025 for $457 million, and retired another 0.75 million shares in Q3 2026. Over the past trailing twelve months alone, total shares outstanding plunged by a massive 6.6%, directly supercharging per-share intrinsic value.
⏩ Potential (Future) Dilution & Overhang: The threat of future dilution is non-existent. Executive stock-based compensation (SBC) is minimal, highly controlled, and vastly outstripped by the sheer velocity of the buybacks. The company currently holds a massive, fully authorized $400 million share repurchase facility actively deployed in the market, mathematically ensuring the share count will continue to aggressively and permanently contract over the next 12 to 24 months.
Q4-A5. Data Integrity Check
Period: TTM/Quarterly standardization (Trailing twelve months ending June 30, 2026 applied across all valuation and fundamental metrics) ➡ (Pass)
Definition: Non-GAAP EPS and standard FCF (Operating Cash Flow minus Capital Expenditures) definitions unified and consistently applied ➡ (Pass)
Number of shares: Diluted weighted average (52.36M shares) utilized for all per-share and total market capitalization calculations ➡ (Pass)
Unit: USD strictly enforced across all comparisons ➡ (Pass)
Single Value Confirmation: All primary SA and disclosure figures successfully reconciled to a single, verified truth point ➡ (Pass)
Q4-A6. Step 4 Key Takeaways
Scoring Rationale:
Accounting anomalies·distortion signals (8/8): The balance sheet and income statement are immaculate and highly transparent; the only anomaly (the severe Q3 AR spike) was clearly explained by management and subsequently resolved in hard cash immediately after the quarter closed.
Cash flow warning signals (6/7): The company boasts structurally elite cash conversion. However, the severe DSO fluctuation warrants a minor, mechanical penalty for intra-quarter volatility, underscoring the working capital vulnerability of relying on federal bureaucracy.
Dilution factors (5/5): The company is destroying shares at a blistering, undeniable pace, providing a massive, unstoppable structural tailwind to per-share intrinsic value and completely negating any SBC overhang.
Step 4 Summary: Maximus possesses a pristine forensic and accounting profile. The company requires negligible capital expenditures, aggressively shrinks its outstanding share count, and rapidly converted its only recent working capital concern into cleared cash, proving the fundamental soundness of its financial reporting.
👔 Step 5: Maximus Management & Shareholder Alignment
Q5-A1. Can You Trust Maximus’s Management? (Guidance Track Record)
Guidance Hit Rate: Management has a long, established history of conservative, highly reliable forecasting. However, executive credibility suffered a severe mechanical hit in Q3 2026 when the company was abruptly forced to slash its full-year FY26 adjusted EPS guidance from a midpoint of $8.40 down to $8.05.
Transparency: Crucially, this guidance cut was not the result of an operational failure, an unforced execution error, or aggressive accounting unraveling. Rather, it was driven by a unilateral, external mandate by the Department of Veterans Affairs to suspend performance incentives while the agency revamps its internal invoicing systems. Management communicated this negative impact with absolute transparency, immediately stripping the assumed $0.35/share incentive out of all Q4 and future models rather than relying on false hope or burying the bad news. This demonstrates exceptionally high integrity and a commitment to radical truth-telling, even when delivering acutely painful news to the market.
Q5-A2. What Are Maximus Insiders Doing?
Insider Trading Status and Context Analysis: Insiders are heavily convicted in the company’s deeply discounted valuation. Over the trailing 12 months, the transaction flow is decisively, overwhelmingly bullish. In February 2026, CEO Bruce Caswell executed a massive, highly visible cluster buy, purchasing three separate tranches of stock on the open market totaling approximately $249,000 at prices between $76.92 and $78.77. On the exact same day, CFO David Mutryn purchased 1,000 shares for $76,000. Confirming the absence of internal panic following the recent Q3 stock collapse, there have been absolutely zero insider sales reported in the last three months.
Evaluating executive confidence signals: Open-market, voluntary purchases of this magnitude by both the Chief Executive Officer and the Chief Financial Officer simultaneously constitute a textbook, undeniable “cluster buy” signal. This reflects immense psychological confidence in the underlying business mechanics and signals definitively that the executives possessing the most intimate knowledge of the VA contract dynamics believe the public market is severely, irrationally mispricing the stock’s future cash flows.
Q5-A3. Is Maximus’s Management Aligned With Shareholders?
Voting Rights and Governance Check: The company operates with a clean, standard single-class voting structure. This ensures highly equitable, proportional representation for all common shareholders, completely avoiding the dictatorial dual-class entrenchment mechanisms that plague many modern technology and services firms.
Incentive alignment assessment: Executive compensation is appropriately and heavily weighted toward performance-based equity rather than bloated, guaranteed base salaries. More importantly, management’s relentless, almost mechanistic execution of the massive $400 million buyback program at 52-week lows perfectly aligns with long-term shareholder value creation. By prioritizing share cancellation over empire-building M&A, executives actively prevent the equity dilution typically caused by excessive Stock-Based Compensation (SBC), ensuring that all margin expansions flow directly to the per-share intrinsic value of the remaining owners.
Q5-A4. Step 5 Key Takeaways
Scoring Rationale:
Management Trust (4/5): Transparency is superb, and the team does not hide bad news. However, the sudden, violent guidance reset—even if entirely driven by an unpredictable external customer action—introduces undeniable near-term forecast friction that must be penalized slightly.
Insider Trends (5/5): Emphatic, synchronized cluster buying by the CEO and CFO in the open market, coupled with zero recent panic selling, provides the ultimate, irrefutable signal of insider conviction.
Governance·Compensation System (5/5): Clean single-class voting and a relentless, proven commitment to massive share count reduction demonstrate flawless, unwavering alignment with minority shareholders.
Step 5 Summary: Maximus is led by a highly transparent, shareholder-friendly executive team whose interests are perfectly, structurally aligned with public investors. This alignment is evidenced by robust open-market insider cluster buying and an aggressive, counter-cyclical share cancellation strategy that heavily penalizes dilution.
⛵ Step 6: Maximus Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Maximus Guidance
Guidance gap and direction analysis: Market sentiment is currently exceptionally weak, bordering on total capitulation following the Q3 earnings print. Analysts universally, and somewhat mechanically, slashed their expectations after management lowered FY26 EPS guidance to the $7.90–$8.20 range. The broader consensus rating degraded rapidly to a “Reduce” or “Hold,” with quantitative entities like Zacks Research violently downgrading the stock to a “Strong Sell” strictly based on the algorithmic momentum of the mechanical earnings cut.
Tracking recent sentiment changes: Over the past 1-3 months, EPS revisions have been universally downward, reflecting deep institutional panic over the VA MDE incentive pause. However, it is highly notable that despite the downgrades, analysts maintain an average price target near $100.00. This implies a massive, glaring disconnect between short-term algorithmic trading downgrades (which react to the guidance cut) and long-term intrinsic value models (which recognize the durability of the underlying cash flows).
Q6-A2. What Is Maximus’s Short Interest?
Institutional Trends: Despite the horrific headline volatility and price collapse, institutional ownership remains incredibly high at roughly 97.2%. This indicates that long-term “smart money” continues to stubbornly anchor the float, recognizing the temporary nature of the contract pause and refusing to dump shares at capitulation multiples.
Short Selling Indicators: Short interest currently sits at 6.03% of the outstanding float (representing roughly 3.10 million shares sold short), carrying a moderate Days-to-Cover ratio of 5.11. While the stock is not currently positioned for a violent, immediate short squeeze, this represents a meaningful, concentrated pocket of bearish positioning. Should the VA contract resolve favorably or the $400M buyback accelerate, this short interest could serve as a highly combustible source of future buying pressure, forcing covering rallies.
Q6-A3. Step 6 Key Takeaways
Scoring Rationale:
Consensus vs Guidance (1/3): The immediate, algorithmic momentum is brutally negative, characterized by widespread downgrades and mechanically lowered estimates following the VA contract revision.
Supply·Short Interest (2/2): Immensely high institutional backing provides a solid, unshakeable floor, and a 6% short interest implies that while bearishness is present, it is highly manageable and sets up a potential contrarian snapback.
Step 6 Summary: Market sentiment is currently mired in a deep capitulation phase driven entirely by panic over the VA incentive suspension. However, heavily entrenched institutional ownership continues to absorb the shock, preventing a total collapse and setting the stage for a contrarian recovery.
🚀 Step 7: Maximus Catalysts & Price Triggers
Q7-A1. What Could Move Maximus Stock? (Top 3 Catalysts)
1 Resolution and Re-Award of the VA MDE Contract
Timing: Next 3-6 months (Early FY27)
Success Conditions: The VA successfully concludes its internal invoicing overhaul and formally awards the massive successor contract to Maximus across all six incumbent regions. Crucially, the new contract immediately reinstates the highly lucrative performance incentive structures, instantly restoring the $0.35 per share in lost quarterly earnings power.
Failure Risk: The VA, bowing to political pressure or budgetary constraints, opts to permanently remove the incentive fee structure entirely, or worse, allocates primary regions to competing vendors, permanently compressing the U.S. Federal Services baseline margin.
2 State-Level Implementation of Medicaid and SNAP Work Requirements
Timing: Next 6-12 months
Success Conditions: Sweeping new federal legislation (such as H.R. 1) forces hesitant state governments to implement complex new administrative requirements for entitlement programs. This drives a massive, unavoidable surge in outsourced outreach, eligibility determination, and engagement volumes for the U.S. Services segment, catapulting it back to mid-single-digit organic growth.
Failure Risk: State governments successfully delay implementation through legal challenges or attempt to absorb the massive administrative burden internally using legacy systems, stunting the segment’s desperately needed growth recovery.
3 Aggressive Deployment of the $400 Million Buyback Authorization
Timing: Next 3-6 months
Success Conditions: Management aggressively and unapologetically capitalizes on the current 35% stock collapse, deploying the remaining $400 million buyback authorization at deeply distressed multiples. This violently shrinks the outstanding share count and artificially engineers massive EPS growth, forcing a multiple re-rating regardless of top-line stagnation.
Failure Risk: Management hoards cash defensively out of fear of further DSO delays or macroeconomic shocks, entirely missing the fleeting window to retire shares at extreme trough valuations.
Q7-A2. Maximus’s Earnings Revision Trend
Tracking EPS estimate changes: Earnings revisions have been brutally, almost violently negative over the past 30 to 90 days. Analysts universally lowered forward estimates immediately following the Q3 2026 report, mechanistically adjusting their models to account for the $0.35 per share hit from the VA incentive pause. The consensus for FY26 EPS was aggressively cut from a previously expected $8.40 down to the new $8.05 midpoint. This violent downward revision cycle has fully flushed all residual optimism out of the stock, decisively resetting the baseline expectations to an ultra-conservative, easily beatable floor.
Q7-A3. Step 7 Key Takeaways
Scoring Rationale:
Catalyst (6/7): The impending VA contract resolution and incoming federal entitlement mandates offer massive, highly asymmetric upside triggers, fundamentally backed by a relentless, price-agnostic buyback floor.
EPS Trend (0/3): The mechanical revisions are universally downward in the immediate term, thoroughly destroying short-term momentum and warranting zero points for trend.
Step 7 Summary: While near-term earnings momentum has cratered due to guidance cuts, the stock is coiled tightly around highly visible, high-impact catalysts—most notably the upcoming VA MDE contract resolution and state-level legislative mandates that promise to violently re-rate the stock upward upon success.
⚖️ Step 8: Is Maximus Fairly Valued? Valuation Analysis
Scoring Rationale: Every single absolute valuation metric trades at deeply distressed, near-panic levels. A highly profitable, wide-moat government contractor trading below 7x forward earnings, backed by an EV/EBITDA under 7x and a PEG ratio of 0.64, signals absolute capitulation pricing that is completely decoupled from the company’s long-term fundamental reality and robust cash generation.
📌 (1) Axis Q8-A1 Score:5
Q8-A2. Maximus vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER
Calculation of peer-to-peer deviation rate: -48.78%
🧮 Calculation Formula: ((Target Forward PER 6.80x - Peer Mean 13.27x) / Peer Mean 13.27x) × 100
Scoring Rationale: Utilizing a highly comparable primary peer group of Booz Allen Hamilton (BAH at 12.20x), ICF International (ICFI at 12.30x), and CACI International (CACI at 19.16x), the peer average forward multiple sits at roughly 13.27x. Maximus, trading at an astonishing 6.80x, represents a staggering 48%+ discount to essentially identical defense and government service peers, revealing a massive, unjustified valuation gap.
📌 (2) Axis Q8-A2 Score:5
Q8-A3. Is Maximus Cheap or Expensive vs Its History?
Comparison Indicators: Trailing PER
Scoring Rationale: Maximus has historically traded at a very stable 5-year median P/E ranging from roughly 16.0x to 20.0x. The current Trailing P/E of 8.57x places the stock firmly at the absolute bottom 0-20% percentile of its historical valuation band. This confirms beyond a doubt that the equity is trading near multi-year, capitulation-level lows rarely seen outside of deep recessions.
📌 (3) Axis Q8-A3 Score:5
Q8-A4. What Growth Is Priced Into Maximus? (Reverse DCF)
Implied Growth Rate:0.0%
1 Methodology: PEG-based inversion
2 Core assumptions: A forward P/E of 6.8x applied to a highly entrenched, high-ROIC business mathematically implies that the broader market is pricing in zero, or actively negative, perpetual growth.
Achievable Growth Rate:4.6%
Basis: Analyst consensus for basic 1-year EPS growth (rebounding from $8.01 to $8.38) despite the current contract headwinds.
Scoring Rationale: Market expectations are completely washed out. The stock is literally priced for terminal decline, yet natural inflation-adjusted government contract escalators and the massive $400M buyback alone mathematically guarantee the company can easily clear the 0% growth hurdle, offering a massive margin of safety.
📌 (4) Axis Q8-A4 Score:3
Q8-A4-1. What Growth Hurdle Does the Market Demand From Maximus? (Reverse DCF Alternative)
➖ Not applicable:
Scoring Rationale: (Not applicable)
📌 (4) Axis Q8-A4-1 Score:➖
Q8-A5. Valuation Cross-Check
Scoring Rationale:
(1) Axis Q8-A1 (Key Valuation Indicator): Very Undervalued
(2) Axis Q8-A2 (Peer-to-peer deviation rate): Very Undervalued
(3) Axis Q8-A3 (Historical Band Position): Very Undervalued
(4) Axis Q8-A4 (Justification for Growth): Undervalued
All four primary valuation axes uniformly, decisively point to extreme undervaluation without a single dissenting metric. The mechanical framework definitively confirms a massive, undeniable margin of safety across every analytical lens.
📌 (5) Axis Q8-A5 Score:0
Q8-A6. Maximus’s Hidden Asset & Stake Valuation
➖ Not applicable:
Scoring Rationale: (Not applicable)
📌 (6) Axis Q8-A6 Score:➖
Q8-A7. Final Valuation Adjustment
Scoring Rationale: The mechanical framework has perfectly and exhaustively captured the extreme distress and highly asymmetric risk-reward profile present in the multiples. No exceptional or subjective override is required.
Commentary: The disciplined valuation framework screams deep undervaluation. The 35% collapse in the stock price over the past year has violently compressed multiples to levels completely disjointed from peers and the company’s own history, establishing a fortress-like margin of safety.
Step 8 Summary: Maximus is currently trading at distressed, absolute capitulation-level multiples. Driven by intense panic over a single, explicitly temporary contract incentive pause, the market has illogically priced an entrenched, high-ROIC government monopoly as if it were entering a terminal decline.
💀 Step 9: What Are the Risks of Maximus? Fatal Risks & Pre-Mortem
Q9-A1. What Are the Biggest Risks to Maximus?
1 Prolonged Extension or Permanent Loss of VA MDE Performance Incentives:
Cause: The Department of Veterans Affairs, bogged down by bureaucratic inertia, decides not to reinstate the highly lucrative incentive fee structure during the upcoming successor contract rebid, or opts to allocate primary, high-volume regions to competing vendors.
Impact: Financial (Permanent, structural baseline reduction in the U.S. Federal Services operating margin).
Mitigation/Monitoring Indicators: Closely monitor the final award details, scope, and pricing structure of the VA MDE draft performance work statement (PWS) expected to be finalized by early calendar 2027.
2 Structural Federal Procurement Freezes and Budget Gridlock:
Cause: Severe, ongoing political gridlock in Washington D.C. leads to prolonged continuing resolutions (CRs) or full government shutdowns, violently stalling the translation of the massive $50.4 billion pipeline into actual contract awards.
Impact: Financial (Stagnation of top-line revenue growth as agencies are forced to resort to flat-funded, low-margin bridge contracts).
Mitigation/Monitoring Indicators: Track the quarterly book-to-bill ratio, which recently dipped to an anemic 0.5x due to these exact procurement delays in the federal civilian market.
3 Post-Medicaid Unwinding Hangover in U.S. Services:
Cause: State governments, facing internal budgetary or IT constraints, fail to implement new legislative outreach mandates, leaving a massive, unfillable revenue hole following the end of the pandemic-era Medicaid redetermination surge.
Impact: Financial (Failure of the U.S. Services segment to return to the promised mid-single-digit organic growth trajectory in Q4 2026).
Mitigation/Monitoring Indicators: Track state-level legislative budgets and carefully audit the Q4 2026 U.S. Services organic growth rate.
Q9-A2. How Sensitive Is Maximus to the Economy?
1 U.S. Federal Budget Constraints (⬇): Austerity measures or prolonged continuing resolutions directly and immediately choke off the funding required for agencies to award massive, new BPO and IT modernization contracts. This heavily delays the conversion of Maximus’s pipeline and compresses near-term growth.
2 Interest Rate Environment (⬇): While operationally insulated from consumer credit cycles, sustained high interest rates would mathematically increase the cost of servicing the company’s $1.65 billion in debt. This slightly increases the hurdle rate for executing aggressive, debt-funded share repurchases, marginally slowing the EPS accretion.
Q9-A3. Maximus Pre-Mortem: What Could Go Wrong?
1 Catastrophic Loss of the VA MDE Franchise: The VA, frustrated by ongoing internal invoicing issues and external political pressure, decides to completely overhaul the provider network. They permanently revoke Maximus’s status as a prime vendor across its historical regions, wiping out a massive, highly profitable pillar of federal revenue overnight.
Early Warning Signal: The VA repeatedly delays the final RFP issuance and extends incumbent bridge contracts with heavily punitive, low-margin terms deep into late 2027.
2 A Devastating Cybersecurity Breach: State-sponsored hackers or ransomware syndicates successfully penetrate Maximus’s vast, highly centralized repositories of sensitive citizen health data (such as Medicaid and Medicare records). This triggers massive federal fines, devastating class-action lawsuits, and immediate debarment from bidding on future government contracts.
Early Warning Signal: An abrupt 8-K filing disclosing a material data exfiltration event, echoing the severity of the 2023 MOVEit vulnerability incident.
3 The AI Margin Miracle Evaporates: Federal and state procurement officers wise up to the massive cost savings generated by Maximus’s AI deployment. They aggressively rewrite future RFPs to claw back those margins for the government, permanently capping the company’s operating leverage.
Early Warning Signal: Operating margins in the U.S. Federal segment suddenly revert from 18.6% back down to historical 12% levels on newly awarded recompetes.
Q9-A4. Risk Adjustment Score
Reason for Scoring: The primary risk is entirely real, explicitly quantified, and currently bleeding into the financial statements. The VA MDE incentive pause has officially been priced into guidance, mechanically reducing EPS by an estimated $0.35 per share, and the difficult federal procurement environment is visibly slowing the book-to-bill ratio. This necessitates a solid Tier 2 deduction as the risk is officially recorded in the numbers and guidance, though it is definitively not existentially threatening to the enterprise.
📊 Risk Adjustment Score:-12 pts
Step 9 Summary: The primary, overriding risk is extreme concentration exposure to the VA MDE contract. While the immediate pain of the incentive pause is already quantified in management’s harshly reset guidance, any permanent structural change to this contract poses a heavy, undeniable ceiling on future margin recovery.
Commentary: The exceptionally strong base score is anchored by the company’s nearly unassailable moat in specialized government health services, an elite ROIC profile, and a relentless, anti-dilutive share repurchase program. The systematic percentile-band methodology demands a maximum premium for the stock’s deeply distressed, capitulation-level valuation. Simultaneously, the disciplined risk framework applies a heavy, quantified penalty to account for the immediate earnings damage inflicted by the VA contract disruption, ensuring a balanced, mathematically sound final rating.
Q10-A2. Should You Buy Maximus? (Recommendation)
Recommendation:Buy
Commentary: Trading at an irrational, distressed 6.8x forward multiple, the broader market has wildly overreacted to an explicitly temporary administrative contract pause. This offers an incredibly rare, highly compelling opportunity to acquire a high-quality, cash-gushing government monopoly at a deep discount, secured by an ironclad margin of safety and a massive $400 million buyback floor.
Q10-A3. Investment Thesis in One Line
Maximus operates as an entrenched, highly profitable tollbooth for government health services trading at a deeply distressed valuation due to a temporary contract hiccup, offering massive asymmetric upside supported by aggressive share repurchases, though investors must remain hyper-vigilant regarding the ultimate resolution of the VA MDE recompete.
Q10-A4. Maximus’s Price Trend & Key Drivers
Stock Price Trends Over the Past 12 Months:Declining 📉
August 06, 2026Q3 2026 Earnings and Guidance Cut
Description: Management shocked the market by aggressively and transparently lowering full-year FY26 EPS guidance from an $8.40 midpoint down to $8.05 due strictly to the VA’s temporary pause on MDE performance incentives, triggering widespread algorithmic analyst downgrades. ➡ Stock Price Plunge
July 01, 2026VA MDE Incentive Pause Initiated
Description: The Department of Veterans Affairs quietly implemented a temporary contractual modification pausing performance incentives, slowly leaking fear and uncertainty into institutional models regarding the fundamental fragility of federal margins. ➡ Steady Downward Pressure
May 07, 2026Q2 2026 Earnings Surprise and Mega-Buyback
Description: The company delivered robust, undeniable margin expansion driven by AI efficiencies and unveiled a massive $400 million share repurchase authorization, briefly restoring immense confidence in the capital allocation story before the VA disruption hit. ➡ Stock Price Surge
Q10-A5. Action Plan
Current Price:$57.76
Buy Zone:$65.00 ($60.00–$70.00)
(1) Calculation of Fundamental Value: The historical 5-year valuation floor for Maximus resides near 16x earnings. Even under the highly penalized, overly conservative worst-case scenario where the VA incentives never return, applying a draconian 11.5x multiple provides a massive intrinsic value buffer that sits well above the current $57 handle.
(2) Momentum Premium/Discount Application: Because the stock is currently mired in a severe downward momentum cycle fueled by algorithmic downgrades and extreme negative sentiment, the framework demands a steep technical discount. We do not chase the falling knife blindly, but firmly and confidently anchor the buy zone below $70.
(3) Conclusion: The appropriate buying price range is $60 to $70, taking full advantage of the market capitulation while leaving ample room for the $400 million buyback floor to stabilize the technical support levels and force a bottom.
Price Target:$92.50
Expected Return:+60.1% (vs. current price)
📍 Select target stock price calculation criteria:
Per share indicator based (Forward PER) — The most accurate methodology for a mature, highly predictable BPO services firm with exceptionally stable free cash flows.
🧮 Price Target Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): Forward EPS $8.05 × 11.5x = $92.58 ➡ rounded to $92.50
Basis for applying the multiple: Peer average and historical trough blending — 11.5x — A heavy conservative discount is applied against the 13.2x peer average to strictly account for the ongoing federal procurement friction and VA contract uncertainty.
Conditions and timing for reaching price target: Achievement relies entirely on the formal re-award of the VA MDE successor contract with reinstated performance incentives in early FY27. This must be combined with the U.S. Services segment posting verifiable, positive organic growth in Q4 2026 to conclusively prove the Medicaid redetermination hangover has passed.
Stop Loss:$49.00 ($47.00–$51.00)
Action trigger upon catalyst achievement:
1 Formal Announcement of the VA MDE Successor Contract Award
Description: Securing the rebid with the performance incentive structure fully intact proves definitively that the Q3 guidance cut was purely a temporary administrative glitch, fundamentally restoring the earnings base. 👉 Increased Holdings (Buy)
2 Q4 2026 U.S. Services Organic Growth Turns Positive
Description: Conclusively proves that state-level outreach mandates are real and accelerating, entirely absorbing the revenue gap left by the Medicaid redetermination cliff. 👉 Hold and Let Run (Wait)
3 Exhaustion of the $400 Million Share Repurchase Authorization
Description: Signals that management has successfully retired another massive block of equity at trough valuations, violently compressing the share count and artificially supercharging forward EPS. 👉 Increased Holdings (Buy)
Action trigger upon risk realization:
1 Loss of a Major VA MDE Region to a Competitor
Description: A catastrophic loss of market share fundamentally alters the baseline revenue profile of the U.S. Federal Services segment, permanently impairing the stock’s long-term earnings power. 👉 Liquidation of Holdings (Sell)
2 OCF Remains Negative for a Second Consecutive Quarter
Description: Proves beyond a doubt that the working capital delay was not a one-off administrative error but a systemic breakdown in federal payment processing, heavily destroying the dividend safety margin. 👉 Reduction in Holdings (Sell)
3 Gross Margins Compress Below 20%
Description: Indicates that the heavily touted AI and automation efficiencies have been completely competed away or effectively legislated out of future contract pricing by aggressive procurement officers. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Wait patiently for the Q4 2026 earnings release to officially confirm that DSO has normalized below 70 days and cash flow has robustly resumed before taking a cautious 50% entry position.
Neutral Investors: Scale into the stock smoothly within the specified Buy Zone, utilizing the secure 2.43% dividend yield to effectively get paid to wait out the VA contract resolution over the next 3-6 months.
Aggressive Investors: Capitalize on the extreme capitulation multiples immediately, heavily front-loading the position to ride the powerful backdraft of management’s aggressive, price-agnostic open-market share repurchases.
🕵️♂️ Deep Dive Analysis
Q1: Is Maximus’s Extreme Dependence on the U.S. Federal Government Its Biggest Weakness?
Analysis: Maximus generates approximately 58% of its total revenue from the U.S. Federal Services segment, making it highly, almost dangerously tethered to the bureaucratic friction, political whims, and budget cycles of Washington D.C. As starkly demonstrated in Q3 2026, a single administrative decision—the VA unilaterally pausing performance incentives to fix an internal invoicing system—instantly wiped $0.35 per share off the company’s full-year earnings trajectory. Furthermore, this extreme concentration exposes the company to severe working capital volatility; a processing delay at one major federal customer spiked DSO to 98 days and dragged operating cash flow into a negative $125 million hole for the quarter. While the recent strategic expansion into defense and national security (a $47 billion TAM) offers a degree of intra-governmental revenue diversification, it fundamentally deepens the company’s ultimate reliance on the federal purse.
Judgment:Neutral — While federal dependence undoubtedly creates immense, highly visible headline volatility and frustrating working capital delays, it simultaneously provides an impenetrable, nearly monopolistic moat. The federal government rarely switches incumbent providers on massive, complex health administration contracts due to the catastrophic political risk of service failure, meaning the revenue—while occasionally lumpy and delayed—is practically guaranteed over the long term.
Q2: Can Maximus’s Distressed 6.8x Forward P/E Be Justified by the Pause in VA MDE Incentives?
Analysis: The market has brutally and mechanistically punished Maximus, compressing its forward multiple to a capitulation-level 6.8x. This extreme pricing explicitly implies that the business is entering a phase of permanent, structural decline. However, the VA MDE incentive pause is a known, quantified, and explicitly temporary administrative hurdle running only through December 31, 2026. Even stripping out the entire incentive margin, Maximus is still projected to generate an adjusted EBITDA margin of 13.0% in Q4 and maintain a massive, compounding stream of free cash flow. Furthermore, pure-play government service peers like Booz Allen Hamilton and ICF International, which face identical federal budget environments and procurement delays, trade comfortably at 12x to 13x forward earnings.
Judgment:Undervalued — The 6.8x multiple is a gross, algorithmic overreaction. The market has incorrectly priced a temporary, 6-month administrative pause as if it were a permanent loss of the entire contract, creating a historically massive margin of safety for investors willing to look past the immediate quarter’s noise.
Q3: Will AI and Automation Permanently Expand Maximus’s Operating Margins?
Analysis: The most profoundly bullish fundamental development for Maximus is its deliberate decoupling of revenue from headcount. In Q3 2026, despite a 5.1% decline in consolidated revenue, the U.S. Federal Services segment posted a massive 18.6% operating margin, up from 18.1% the prior year. Management explicitly attributes this to the deployment of proprietary AI-enabled tools and workflow automation across five major contracts, which drove a 3.5% standalone margin improvement. With AI requirements now actively embedded in 75% to 80% of all new bids, the company is fundamentally transforming from a low-margin, labor-intensive BPO into a high-margin, highly scalable tech-enabled platform.
Judgment:Positive — Yes. As long as the company maintains its fixed-price and performance-based contract structures, the massive cost savings generated by AI triage and automation will fall directly to the bottom line, permanently elevating the baseline ROIC and protecting profits from wage inflation.
Q4: Can the U.S. Services Segment Successfully Rebound Post-Medicaid Redeterminations?
Analysis: The U.S. Services segment has been a major perceived drag on the top line, shrinking 7.7% in FY25 as the massive, one-time surge of pandemic-era Medicaid unwinding work predictably evaporated. However, management has firmly and repeatedly guided that the segment will return to positive mid-single-digit organic growth in Q4 2026. This turnaround is predicated not on hope, but on rigid new legislative mandates (such as H.R. 1), which force states to implement stricter work requirements and engagement outreach for Medicaid and SNAP beneficiaries. As states face a massive 25% increase in their SNAP administrative cost-share beginning in late 2027, their reliance on Maximus’s highly cost-efficient outsourced program integrity tools will inevitably spike.
Judgment:Positive — The Medicaid redetermination hangover has fully washed through the year-over-year comparables. The structural complexity and financial burden of new federal entitlement mandates guarantee that understaffed, technologically outdated state governments will be forced to outsource administrative outreach to Maximus, ensuring a definitive return to baseline growth.
Q5: Does the New $400 Million Buyback Program Signal an Imminent Bottom for the Stock?
Analysis: Maximus’s capital allocation strategy is ruthlessly efficient and highly opportunistic. In FY25, the company spent $457 million to vaporize 5.8 million shares, representing over 10% of the entire company. Following the Q2 2026 earnings, the Board confidently reloaded the weapon with a fresh $400 million authorization. At the current deeply distressed market capitalization of roughly $3.0 billion, fully deploying this $400 million would retire an astonishing 13% of the remaining float. Furthermore, synchronized open-market cluster purchases by the CEO and CFO in February completely validate that internal models view the current price as absurdly cheap.
Judgment:Positive — Absolutely. The sheer mathematical force of a potential 13% float reduction provides an impenetrable concrete floor under the stock price. Any investor selling at these capitulation levels is directly and unwittingly subsidizing the massive accretion of per-share value for the remaining, patient owners.
Q6: How Damaging is the Divestiture of the International Employment Services Businesses?
Analysis: In Q1 2025, Maximus absorbed approximately $38 million in divestiture-related charges to exit its employment services businesses in Australia and South Korea. These charges, driven largely by accumulated foreign exchange losses, superficially damaged near-term GAAP earnings. However, strategically, this was a highly necessary amputation. The employment services contracts were notoriously low-margin, highly cyclical, and diluted the consolidated ROIC. By shedding these units, the Outside the U.S. segment has shrunk its revenue base by roughly $100 million but eliminated a persistent bleed, allowing the division to refocus entirely on high-margin clinical assessments (like the new $1B Functional Assessment Services contract in the UK) and target consistent break-even profitability.
Judgment:Positive — The divestitures represent a textbook example of addition by subtraction. Management correctly prioritized margin quality and capital efficiency over raw, unprofitable revenue growth, establishing a much healthier baseline for the international segment.
Q7: Are the Recent Days Sales Outstanding (DSO) Spikes a Systemic Solvency Threat?
Analysis: In Q3 2026, Maximus reported a terrifying spike in DSO to 98 days, leading directly to a $125 million operating cash outflow for the quarter. In many industries, this signals a systemic solvency crisis or a breakdown in client relationships. However, in the context of federal contracting, this is a known, albeit frustrating, mechanical hazard. Management transparently attributed the delay to a single federal customer undergoing administrative processing hurdles. The ultimate proof of solvency arrived in July, post-quarter, when Maximus successfully collected $245 million from this exact client. Furthermore, the company’s $1.65 billion gross debt structure and 2.0x leverage ratio provide more than enough liquidity to bridge these temporary working capital gaps without threatening the dividend or the buyback program.
Judgment:Neutral — While absolutely not a systemic solvency threat, the incident serves as a stark reminder of the liquidity friction inherent in government contracting. It underscores why Maximus must maintain a conservatively levered balance sheet.
Q8: Will the Expansion into Defense and National Security Dilute Maximus’s Core Moat?
Analysis: Maximus has historically built its moat entirely around civilian health and human services (HHS). Recently, however, the company identified a $47 billion total addressable market in defense and national security, securing notable wins with the Air Force, TSA, and cyber command centers. Critics argue that moving away from HHS pits Maximus against entrenched defense primes (like Leidos and CACI) where it holds no inherent advantage. However, Maximus is strictly targeting the administrative, cyber, and contact-center layers of these agencies—areas where its proprietary TXM (Total Experience Management) platform scales perfectly. It is not attempting to build weapon systems, but rather deploying its existing operational efficiencies into new government silos.
Judgment:Positive — The expansion is highly strategic. By leveraging its existing, massive contact-center infrastructure and AI triage tools, Maximus can cross-sell its services into the defense sector, dramatically expanding its TAM without requiring capital-heavy pivots or diluting its core operational competencies.
Q9: Is the 2.43% Dividend Yield Safe Amidst Cash Flow Volatility?
Analysis: With a current annual payout of $1.32 per share, Maximus yields approximately 2.43%. Despite the Q3 2026 negative free cash flow event, the dividend remains exceptionally safe. The payout ratio sits at a highly conservative 19.59% of trailing earnings. The company generates over $360 million in normalized annual free cash flow, and its interest coverage ratio of 6.49x proves that debt servicing will not crowd out shareholder returns. Management’s decision to maintain the dividend and continue buybacks even during the 98-day DSO spike explicitly signals their supreme confidence in the durability of the cash conversion cycle.
Judgment:Positive — The dividend is ironclad. The ultra-low payout ratio leaves massive room for future dividend growth, and the structural cash generation of the business easily covers the distribution even in the event of severe federal payment delays.
Q10: How Should Investors Interpret the Extreme Divergence Between Analyst Ratings and Price Targets?
Analysis: Following the Q3 2026 guidance cut, analysts rapidly downgraded the stock’s rating, pushing the consensus to “Reduce” or “Hold,” with some algorithms triggering a “Strong Sell.” Yet, perplexingly, the average analyst price target remains anchored at $92.50—a massive 60% premium to the current $57.76 trading price. This divergence occurs because ratings are heavily momentum-driven, punishing the stock for the immediate, 6-month earnings friction caused by the VA incentive pause. Conversely, price targets are derived from longer-term discounted cash flow (DCF) and historical multiple models, which mathematically recognize that a company with a 13% ROIC and a massive buyback floor is intrinsically worth nearly $100 a share.
Judgment:Positive — For long-term investors, this divergence is the ultimate buy signal. It confirms that the underlying intrinsic value remains robust, while short-term, momentum-driven downgrades have artificially crushed the entry price, creating a rare, asymmetric margin of safety.